Skip to content
thestock.space

On 6 Nov 2026, Shree Ganesh Remedies was priced at ₹625.85, or 52.1× trailing earnings, against an industry P/E of 28.7×, and the shares are 17% below their 52-week high. It earns ROCE of 15% and ROE of 7.6%, and sales and net profit grew 6.2% and 1.4% a year over 3 years. Debt is 0.16× equity. It is a small-cap company with a market cap of ₹803 Cr, ranked 75th of 154 Drug Manufacturers (Specialty & Generic) companies by market cap; the shares rose 19% over the past year.

As of 6 Nov 2026Prices are delayed about 15 minutes; fundamentals are from the quarter ended Jun 2026.How we calculate this

past year
Open
₹647.00
Day high
₹647.00
Day low
₹621.75
Prev. close
₹631.60
Volume
8.1K

Health check

1 good · 2 fair · 3 to check
  • ReturnsIn line

    +19.4% over a year, better than 3 of 7 peers.

  • Price tagPricier

    P/E 52.1 vs industry 28.7.

  • GrowthSlow

    Sales +6.2%, profit +1.4% a year over 3 years.

  • ProfitabilityAverage

    ROCE 14.7% vs peer median 17.9%.

  • Balance sheetSolid

    Debt 0.16× equity, interest covered 8.1×.

  • Red flags4 to check

    Return on equity is low at 7.6%.

Compared with 7 industry peers. Computed from reported figures. Educational, not a recommendation.

Drug Manufacturers - Specialty & Generic

153 listed peers. Screen the industry

Small cap

₹803 Cr, #75 of 154 in its industry by size.

Defensive

Beta 0.51 vs the NIFTY 50: moves less than the market.

Key metrics

Last 12 months to Jun 2026: sales ₹92 Cr · profit ₹12 Cr
Market cap
₹803 Cr
Small cap
P/E
52.1
Industry 28.7
Price to book
4.85
Peers 4.99
Dividend yield
0.00%
ROE
7.6%
Peers 14.7%
ROCE
14.7%
Peers 17.9%
Debt to equity
0.16
Debt ₹26 Cr
EPS (TTM)
₹12.02
Face value ₹10
OPM (TTM)
31.4%
Net margin 13.2%
Sales growth
−41.8%
Latest quarter vs a year ago
Profit growth
−67.5%
Latest quarter vs a year ago
Price to sales
8.74
EV/EBITDA 30.6

Strengths and risks

Strengths

  • Positive operating cash flow in each of the last 4 years.

Risks to check

  • Return on equity is low at 7.6%.
  • Quarterly profit down 67.5% on a year ago.
  • Quarterly sales down 41.8% on a year ago.
  • P/E of 52.1 against an industry P/E of 28.7.

Derived automatically from reported figures. Not a recommendation.

About Shree Ganesh Remedies

Shree Ganesh Remedies Limited engages in the manufacture and sale of pharmaceutical drug intermediates for active pharmaceutical ingredient (API) and fine chemicals in India and internationally. The company offers anti-arrhythmic, anti-cancer, anti-depressant, anti-diabetic, anti-diarrheal, antifungal, antihistamine, anti-inflammatory, anti-parasitic, anti-psychotic, anticholinergic, birth-control, cardiovascular, gastrointestinal, neurological disorder,…

Headquarters
Ankleshwar
Employees
224
Sector
Healthcare
ISIN
INE414Y01015
Website
ganeshremedies.com

Price range

52 weeks

₹490.00₹749.85

Today

₹621.75₹647.00
Avg volume (3M)
19.3K
1-year return
plus 19.4%
From 52-week high
minus 16.5%

Peers · Drug Manufacturers - Specialty & Generic

Compare with peersScreen the whole industry
Company
SUNPHARMASun Pharmaceutical Industries1,860.00plus 1.69%4,46,27640.74.9917.9%13.1%28.2%10.4%10.6%0.86%plus 8.2%
DIVISLABDivi's Laboratories10,320.50plus 1.78%2,73,97793.616.3519.0%16.2%34.9%11.0%12.1%0.29%plus 49.0%
TORNTPHARMTorrent Pharmaceuticals4,750.00plus 0.85%1,80,67580.29.839.1%15.7%33.7%13.3%20.2%0.80%plus 31.7%
LAURUSLABSLaurus Labs2,340.00minus 0.26%1,26,43394.420.8619.5%24.0%30.4%3.8%4.0%0.09%plus 138.6%
ZYDUSLIFEZydus Lifesciences1,197.90plus 0.41%1,19,49128.64.2919.0%14.7%26.2%16.5%37.0%0.08%plus 22.8%
DRREDDYDr. Reddy's Laboratories1,373.00plus 0.51%1,14,46240.92.9614.2%7.3%15.9%11.0%−1.7%0.58%plus 13.8%
CIPLACipla1,411.00plus 0.49%1,13,99339.43.2214.9%8.3%17.3%7.2%11.5%0.92%minus 6.6%
SGRLShree Ganesh Remedies625.85minus 0.91%80352.14.85–7.6%31.4%6.2%1.4%0.00%plus 19.4%
Median of 7 peers–0.51%1,26,43340.94.9917.9%14.7%28.2%11.0%11.5%0.58%22.8%

Quarterly results

Consolidated, ₹ crore
SalesSelect a row below to chart it
₹ CrJun 25Sep 25Dec 25Mar 26Jun 26
24.730.321.133.214.4
17.420.714.421.811
7.39.66.711.43.4
29.6%31.7%31.9%34.3%23.3%
0.70.70.710.9
0.910.70.90.3
2.42.62.72.82.4
4.66.748.71.5
25.1%26.2%22.4%28.1%26.8%
3.453.16.31.1
2.683.862.414.880.87

Profit & loss

Yearly, ₹ crore
Sales CAGR 3Y
+6.2%
Profit CAGR 3Y
+1.4%
EPS CAGR 3Y
−0.4%
ROE
7.6%
Net profitSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
90.2125107108
–+38.3%minus 14.7%+1.5%
66.18366.772.5
24.141.839.835.6
26.7%33.5%37.3%32.9%
2.42.82.31.5
00.523.4
3.86.19.610.5
−0.10.20.80.9
22.638.231.324
24.6%26.3%26.2%26.0%
1728.123.117.8
–+65.1%minus 17.9%minus 23.0%
14.0122.3417.9613.83

Forecast

Your assumptions, not a prediction

Balance sheet

At each financial year end, ₹ crore
Total assetsSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
12.512.812.812.8
76.4109132150
33.536.438.430.8
21.412.48.413.9
144171192208
76.499.1112119
41.818.617.314.2
0.50.10.10.1
11.220.528.225.9
1432.634.148.7
144171192208

Cash flow

Yearly, ₹ crore
Cash from operationsSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
1730.430.723.7
−53.6−33−35.7−9.9
41.39.8−1.1−11.7
4.87.3−6.12.2
−51.6−31.1−23.2−16.6
−34.6−0.77.57.1
−0.6−0.6––

Shareholding pattern

Source: NSE filings

NSE hasn’t returned a shareholding pattern for this company.

Major shareholders

NSE filing

Filings & events

News

No recent news coverage found.

My notes

Private to you